Soligenix Inc（SNGX）の財務SNGXSoligenix Inc

Soligenix Inc (SNGX) generates its revenue primarily from Specialized BioTherapeutics, which accounts for 100.0% of total sales, equivalent to $2.34K. Understanding this concentration is critical for investors evaluating how SNGX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Soligenix Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -241.65%, provide a clear picture of how effectively SNGX converts its operational activities into shareholder value.

In the context of the broader market, SNGX competes directly with industry leaders such as CNSP and ALZN. With a market capitalization of $8.71M, it holds a significant position in the sector. When comparing efficiency, SNGX's gross margin of N/A stands against CNSP's N/A and ALZN's N/A. Such benchmarking helps identify whether Soligenix Inc is trading at a premium or discount relative to its financial performance.

Soligenix has reported consistent net losses, with the latest net income for Q2 2026 at -1,987,354 USD. The company has a negative EPS of -0.12 for Q2 2026, indicating ongoing financial struggles.